Q BioMed (OTCQB: QBIO) (“the Company”) CEO Denis Corin called in to SmallCapVoice.com to discuss the recent news and events for the Company. QBIO issued a key development regarding new distribution agreement for QBIO’s non-opioid metastatic cancer bone pain drug, Strontium89 and what it means for this company. In the interview Corin highlighted the enormous potential market size internationally and where QBIO will focus on first geographically.
In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with Strontium89,. Strontium89 is administered once every 3 months via injection, and patients can be re-treated if needed. With an estimated 10 million people living with bone metastases, Q BioMed anticipates broad market re-acceptance for this well-established, non-opioid option for bone pain management.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Please visit http://www.QBioMed.com and sign up for regular updates.
This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $1,500.00 from the company on 7-8-2020 for 30 days of Audio Interview service and Social Media Coverage.